Concorde Asset Management’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$755K Sell
3,088
-719
-19% -$167K 0.37% 60
2025
Q4
$788K Buy
3,807
+13
+0.3% +$2.57K 0.32% 69
2025
Q3
$705K Buy
+3,794
New +$650K 0.29% 72
2025
Q1
$726K Sell
4,805
-197
-4% -$30.8K 0.39% 34
2024
Q4
$723K Sell
5,002
-8
-0.2% -$1.24K 0.38% 41
2024
Q3
$812K Buy
5,010
+124
+3% +$19.8K 0.46% 34
2024
Q2
$714K Sell
4,886
-59
-1% -$8.78K 0.44% 33
2024
Q1
$782K Sell
4,945
-177
-3% -$28.2K 0.54% 29
2023
Q4
$756K Buy
5,122
+389
+8% +$59.6K 0.51% 31
2023
Q3
$737K Buy
4,733
+2,275
+93% +$375K 0.66% 31
2023
Q2
$394K Buy
2,458
+184
+8% +$29.7K 0.36% 59
2023
Q1
$336K Sell
2,274
-189
-8% -$30.5K 0.4% 49
2022
Q4
$407K Sell
2,463
-814
-25% -$141K 0.36% 67
2022
Q3
$449K Buy
3,277
+202
+7% +$34.2K 0.5% 63
2022
Q2
$451K Buy
3,075
+605
+24% +$108K 0.68% 42
2022
Q1
$411K Buy
2,470
+106
+4% +$18K 0.27% 87
2021
Q4
$396K Sell
2,364
-460
-16% -$75.3K 0.24% 114
2021
Q3
$457K Sell
2,824
-20
-0.7% -$3.41K 0.26% 122
2021
Q2
$462K Sell
2,844
-132
-4% -$21.9K 0.26% 99
2021
Q1
$480K Buy
2,976
+10
+0.3% +$1.62K 0.28% 92
2020
Q4
$442K Sell
2,966
-443
-13% -$65.4K 0.25% 82
2020
Q3
$466K Buy
3,409
+1,608
+89% +$238K 0.27% 97
2020
Q2
$216K Sell
1,801
-2,904
-62% -$423K 0.18% 112
2020
Q1
$617K Sell
4,705
-317
-6% -$45K 0.63% 39
2019
Q4
$730K Sell
5,022
-332
-6% -$45K 0.51% 56
2019
Q3
$693K Sell
5,354
-1,528
-22% -$201K 0.53% 55
2019
Q2
$960K Sell
6,882
-552
-7% -$76.4K 0.56% 55
2019
Q1
$1.04M Buy
7,434
+174
+2% +$23.3K 0.67% 43
2018
Q4
$937K Sell
7,260
-54
-0.7% -$7.53K 0.79% 34
2018
Q3
$1.01M Sell
7,314
-854
-10% -$113K 0.99% 28
2018
Q2
$992K Sell
8,168
-1,508
-16% -$188K 1.13% 22
2018
Q1
$1.25M Buy
9,676
+379
+4% +$51.2K 1.53% 15
2017
Q4
$1.3M Sell
9,297
-3,994
-30% -$556K 1.64% 14
2017
Q3
$1.73M Buy
13,291
+3,534
+36% +$468K 1.5% 8
2017
Q2
$1.29M Buy
9,757
+693
+8% +$88.4K 1.74% 11
2017
Q1
$1.13M Buy
9,064
+4,071
+82% +$486K 1.86% 14
2016
Q4
$575K Sell
4,993
-901
-15% -$104K 1.03% 32
2016
Q3
$692K Buy
5,894
+462
+9% +$56K 0.87% 34
2016
Q2
$658K Buy
5,432
+1,621
+43% +$184K 0.65% 33
2016
Q1
$412K Buy
3,811
+973
+34% +$101K 0.47% 54
2015
Q4
$292K Sell
2,838
-925
-25% -$93K 0.33% 76
2015
Q3
$353K Sell
3,763
-1,406
-27% -$136K 0.6% 58
2015
Q2
$514K Sell
5,169
-1,959
-27% -$196K 0.65% 39
2015
Q1
$717K Sell
7,128
-459
-6% -$46.7K 0.82% 28
2014
Q4
$584K Buy
+7,587
New +$800K 0.73% 34

Other funds holding JNJ

Concorde Asset Management's JNJ Position: Q1 2026 in Review

Concorde Asset Management reduced its Johnson & Johnson (JNJ) stake by 19% in Q1 2026, selling an estimated $167K and leaving 3,088 shares worth $755K. The position accounts for 0.37% of the portfolio, ranked #60.

Concorde Asset Management first reported a position in JNJ in Q4 2014 and has held it in 45 quarters since. The position peaked at $1.73M in Q3 2017. 4,616 funds tracked by Wall St. Rank hold JNJ as of Q1 2026.

  • Concorde Asset Management held 3,088 shares of Johnson & Johnson worth $755K as of Q1 2026.
  • Concorde Asset Management sold 719 Johnson & Johnson shares in Q1 2026, an estimated $167K.
  • Johnson & Johnson made up 0.37% of Concorde Asset Management's portfolio in Q1 2026, its #60 holding.
  • Concorde Asset Management first reported a position in Johnson & Johnson in Q4 2014 and has held it in 45 quarters since.
  • Concorde Asset Management's Johnson & Johnson position peaked at $1.73M in Q3 2017.
  • 4,616 funds tracked by Wall St. Rank held Johnson & Johnson as of Q1 2026.

Based on Concorde Asset Management's 13F filing for Q1 2026, filed 1 Jun 2026.